Ellipses pays for global rights to SunRock compound

25 May 2022

An exclusive licensing agreement has been agreed by SunRock Biopharma, a Spanish company that is developing a portfolio of innovative bispecific antibodies to treat incurable cancer, and UK-based oncology-focused drug development firm, Ellipses Pharma.

The deal relates to SRB22, a fully human bifunctional HER3:TRAIL fusion protein, which going forward will be known as EP0017.

Under the agreement, Ellipses has been granted global rights to develop and commercialize EP0017 and will assume the full cost and responsibility for the remaining pre-clinical and clinical development of the compound.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK